Tremelimumab Failed to Extend Mesothelioma Survival Rates

The highly touted immunotherapy drug tremelimumab failed to extend the lives of malignant mesothelioma patients, according to the London-based manufacturer after it ended its multicenter clinical trial Monday. Researchers were testing tremelimumab — with considerable fanfare — as a second- and third-line treatment for unresectable mesothelioma in a phase IIb trial. The immunotherapy drug already had shown success with other cancers. “We are disappointed that tremelimumab monotherapy did not demonstrate a survival benefit in this patient population,” Robert Iannone, head of immuno-oncology at AstraZeneca said in a statement released Monday. “We remain confident in tremelimumab’s clinical activity in combination.” The announcement came less than a month after a report ...

from MedWorm: Mesothelioma http://medworm.com/index.php?rid=168287031&cid=c_409_55_f&fid=36962&url=http%3A%2F%2Fwww.asbestos.com%2Fnews%2F2016%2F03%2F01%2Fastrazeneca-stops-tremelimumab-mesothelioma-clinical-trial%2F